121PD Two different treatment options for patients with recurrent glioblastoma in the same hospital

Abstract

Aim: The prognosis of recurrent glioblastoma (GB) is poor. The median survival after progression to Stupp protocol is 3-6 months. After the implementation of the NeuroCommittee (CNON) in our center, second treatment options have changed life expectancy without reducing the quality of life.Objectives: Show the selection criteria for second-line treatments in GB. Show overall survival (OS) and progression free survival (PFS) for each treatment group. Methods: We selected 18 patients with recurrent GB treated with surgery + radiotherapy + chemotherapy according Stupp protocol, between January 2010 and December 2013. After assessing the results in CNON, we differenciate two groups: Group 1 (n = 8), Patients who underwent surgical re-intervention + Carmustine implant polymers vs Group 2 (n = 10) those who could not benefit from surgery and received bevacizumab + Irinotecan. We analyzed 20 variables in each patient. Results: In the Group 1 median OS was 10 months (CI 95%: 4,762-15.238), and the PFS was 8 months (CI 95% 5,772). In the Group 2 median OS was 35.15 months (CI 95%,) and the FPS was 20 months (CI 95% 0 -40.144 months). In both groups morbidity and toxicity were acceptable and the quality of life was no affected. Conclusions: Since the establishment by the CNON of a protocol for monitoring and second-line treatment in patients with GB, the overall survival has increased significantly. Of the two options presented, it seems more benefit treatment with Avastin + irinotecan and although the sample size is small, we should think in the adoption of more aggressive therapeutic options in the future. Disclosure: All authors have declared no conflicts of interest.